Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6476078B2 · kind B2 · utility
20Cited by
37References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2001 |
| Grant date | Nov 5, 2002 |
| Priority date | — |
| Expiry date | Jan 29, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2059
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are disclosed for the treatment and prevention of male and female sexual function disorders which comprise a racemic or optically pure sibutramine metabolite and a phosphodiesterase inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.